Tamoxifen stimulates calcium entry into human platelets

Area of Science:

• Pharmacology
• Hematology
• Oncology

Background:

• Tamoxifen is a crucial anti-estrogenic drug for breast cancer treatment and prevention.
• Tamoxifen use is associated with an increased risk of developing thrombosis.
• Understanding the pro-thrombotic mechanisms of tamoxifen is critical for patient safety.

Purpose of the Study:

• To investigate the effect of tamoxifen on intracellular calcium levels in human platelets.
• To determine the specific molecular mechanisms underlying tamoxifen-induced calcium changes.
• To explore the contribution of tamoxifen's calcium-mobilizing properties to thrombosis risk.

Main Methods:

• Measurement of intracellular free calcium ([Ca2+]i) in human platelets using various agonists.
• Assessment of tamoxifen's synergistic effects with thrombin, ADP, and vasopressin.
• Evaluation of the role of tamoxifen metabolites and chemical derivatives in calcium regulation.

Main Results:

• Tamoxifen significantly increased intracellular free calcium ([Ca2+]i) in human platelets.
• Tamoxifen demonstrated synergistic effects with thrombin, ADP, and vasopressin on [Ca2+]i.
• The phospholipase C inhibitor U-73122 blocked tamoxifen-induced [Ca2+]i elevation, while 4-hydroxytamoxifen also increased [Ca2+]i.
• The dimethylaminoethyl moiety was identified as crucial for tamoxifen's calcium agonist activity.

Conclusions:

• Tamoxifen's ability to rapidly increase platelet intracellular calcium contributes to platelet activation.
• Synergistic effects with other platelet agonists may enhance tamoxifen's pro-thrombotic potential.
• These findings highlight a potential mechanism for tamoxifen-induced thrombosis, informing clinical risk assessment.